OncoMatch/Clinical Trials/NCT06800313
A Study of HLD-0915 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
Is NCT06800313 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies HLD-0915 for prostate cancer metastatic disease.
Treatment: HLD-0915 — Assessment of the safety and efficacy of HLD-0915 as monotherapy in patients with metastatic castration resistant prostate cancer (mCRPC) that have progressed on prior systemic therapies, once a recommended dose for expansion (RDE) has been determined in Phase 1 of the trial.
Check if I qualifyExtracted eligibility criteria
Cancer type
Prostate Cancer
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received:
Patients must have progressed on prior line(s) of therapy.
Must have received: androgen-deprivation therapy
Patients must have prior orchiectomy and/or ongoing androgen-deprivation therapy and a castrate level of serum testosterone.
Cannot have received: systemic anti-cancer therapy
Exception: washout period of at least 2 weeks prior to first dose of study drug; certain exceptions require longer washout
Has received systemic anti-cancer therapy (cytotoxic chemotherapy, biologic agent, checkpoint inhibitors, or radiation therapy) or investigational drugs within 2 weeks prior to first dose of study drug with certain exceptions requiring longer washout periods.
Lab requirements
Blood counts
adequate hematological function
Kidney function
adequate renal function
Liver function
adequate hepatic function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Sarah Cannon Research Institute at HealthONE · Denver, Colorado
- Yale - New Haven Hospital - Yale Cancer Center · New Haven, Connecticut
- Florida Cancer Specialists · Sarasota, Florida
- Massachusetts General Hospital · Boston, Massachusetts
- START Midwest, LLC · Grand Rapids, Michigan
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify